PGR and breast carcinoma: Several multigene assays have been developed to predict the risk of recurrence in patients with pN0-N1, ER+ breast cancer; these assays should be more precise than forecasts based on traditional clinical prognostic factors or the status of HRs (ER or PR) and/or HER212, 15, 16, 18.